Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis
NCT03067753Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2016
- Primary completion
- Sep 2019
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of monosialotetrahexosylganglioside in Cerebral radiation necrosis (CRN), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 3 months. Status: unknown.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
Cerebral radiation necrosis (CRN)
Beyond the preview
Go deeper on NCT03067753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03067753.